Refinement of your best leads
In this stage, focus is to enhance efficacy, safety, and pharmacological properties of promising lead compounds, for their development as effective drug candidates.
We support your lead optimization efforts, giving you valuable insights and early confidence in your project.
"At AstraZeneca, we are applying CETSA in hit identification and lead optimization to identify and characterize compounds for a number of novel targets."
Thomas Lundbäck, Senior Director
AstraZeneca
"Our small molecule drug discovery project was seeking a robust assay allowing to screen against the target of interest expressed in its natural cellular environment.
Pelago Bioscience's expertise in drug discovery projects, specifically in the CETSA platform and high throughput screens was the key to achieving our goals.
We found Pelago's team to be professional, knowledgeable, flexible and dedicated. We highly recommend Pelago Bioscience for drug discovery projects."
Po-Shun Lee, Chief Medical Officer
Generian
"Using our world leading expertise in CETSA we have created a faster and more efficient drug discovery process. We take great pride in knowing our customers are bringing new medicines to market more quickly thanks to our help."
Michael Dabrowski, CEO and Co-founder
Pelago Bioscience
"Pelago Bioscience offers exceptional technical expertise in all aspects of target deconvolution using
CETSA – including study design, sample preparation, LC-MS data acquisition, and statistical processing.
Our collaboration always proceeded effectively due to Pelago Bioscience's responsiveness, scientific commitment, and dedication to clients resulting in delivery of impactful scientific results."
Benjamin Fontaine, Scientist
LifeMine Therapeutics
